x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:15:30

Progress in Breast Cancer Care: Translating SABCS...

CME/CE ·

2026/01/30

Faculty: Charles E. Geyer Jr., MD, FACP Faculty: Komal Jhaveri, MD, FACP This online educational activity equips clinicians with up-to-date, practice-changing insights from SABCS 2025. Experts review pivotal data across early-stage and metastatic breast cancer, including advances in HER2- and TROP2-directed ADCs, and discuss how these findings can meaningfully inform treatment selection. Participants will learn how to apply new evidence to expand therapeutic options, improve

en

00:14:00

Practical Perspectives in Myasthenia Gravis #2:...

CME/CE ·

2025/12/31

Faculty: Diana Castro, MD Faculty: Jonathan Strober, MD This discussion between Drs. Diana Castro and Jonathan Strober focuses on the clinical utility of patient stratification and antibody profiling in generalized myasthenia gravis (gMG). The conversation addresses how age of onset, antibody status (acetylcholine receptor, MuSK, LRP4), and comorbidities can influence diagnosis and management plans. The speakers highlight the limitations of current pediatric assessment tools and

en

00:14:45

Practical Perspectives in Myasthenia Gravis #3:...

CME/CE ·

2025/12/31

Faculty: Diana Castro, MD Faculty: Jonathan Strober, MD Drs. Diana Castro and Jonathan Strober discuss treatment strategies for generalized myasthenia gravis (gMG), focusing on pediatric and adolescent care. They review traditional therapies and newer agents, such as FcRn and complement inhibitors, highlighting the role of antibody status and considerations for thymectomy. The conversation also addresses monitoring challenges, including limitations of clinical scales and the

en

00:11:30

Practical Perspectives in Myasthenia Gravis # 1:...

CME/CE ·

2025/12/31

Faculty: Diana Castro, MD Faculty: Jonathan Strober, MD Drs. Jonathan Strober and Diana Castro examine the diagnostic approach to generalized myasthenia gravis (gMG), with a focus on age-related differences in clinical presentation. They describe early signs in pediatric patients—such as ptosis and impaired extraocular movements—and contrast these with the fluctuating fatigue, bulbar involvement, and proximal muscle weakness more commonly seen in adults. The discussion includes

en

00:44:30

Optimizing Multidisciplinary Approaches in the...

CME/CE ·

2025/12/16

Faculty: Brian Slomovitz, MD This activity focuses on optimizing multidisciplinary strategies in the guideline-driven management of cervical and endometrial cancers. Dr. Brian Slomovitz presents recent and emerging clinical data for immunotherapy-based treatment strategies, explores the role of screening and biomarkers, and emphasizes interprofessional collaboration across oncology specialties. Case-based learning contextualizes key concepts and highlights guideline-concordant care for

en

00:05:15

Patient Perspective: Navigating TGCT...

CME/CE ·

2025/12/15

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the

en

00:05:45

Emerging Evidence in Focus: Interpreting Data on...

CME/CE ·

2025/12/15

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the

en

00:04:45

Applying the Evidence: TGCT Treatment Insights for...

CME/CE ·

2025/12/15

Faculty: A.J. Gelderblom, MD, PhD Faculty: Chelsea Cole, MD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported

en

00:05:00

The Tumor That’s Not So Tiny: Understanding the...

CME/CE ·

2025/12/15

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the

en

00:05:00

Surgical Crossroads: Practical Considerations for...

CME/CE ·

2025/12/15

Faculty: A.J. Gelderblom, MD, PhD Faculty: Michiel van de Sande, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and

en

00:05:30

All Sides of the Joint: Integrated TGCT Care Across...

CME/CE ·

2025/12/15

Faculty: A.J. Gelderblom, MD, PhD Faculty: Michiel van de Sande, MD, PhD Faculty: Chelsea Cole, MD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus

en

00:04:45

Unlocking the CSF1R Code: Targeted Pathways and...

CME/CE ·

2025/12/15

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the

en

00:05:00

Beyond the Scalpel: When TGCT Surgery Isn’t the Solution

CME/CE ·

2025/12/15

Faculty: Michiel van de Sande, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture

en

00:04:45

Clinical Evidence in Focus: Interpreting Data on...

CME/CE ·

2025/12/15

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the

en

00:05:15

The Safety Equation: Managing Adverse Events...

CME/CE ·

2025/12/15

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the

en

00:05:00

Minimal Hepatic Encephalopathy: A Covert Operation?

CME/CE ·

2025/12/11

Faculty: Nancy S. Reau, MD This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing

en

00:04:30

The Slippery Slope of Overt Hepatic Encephalopathy

CME/CE ·

2025/12/11

Faculty: Arun B. Jesudian, MD Faculty: Nancy S. Reau, MD This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and

en

00:04:45

Current Treatment of Hepatic Encephalopathy: Is It...

CME/CE ·

2025/12/11

Faculty: Arun B. Jesudian, MD This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and

en

00:05:00

Minimal Hepatic Encephalopathy: Hiding in Plain Sight?

CME/CE ·

2025/12/11

Faculty: Arun B. Jesudian, MD Faculty: Nancy S. Reau, MD This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and

en

00:05:15

Optimizing Care of the Hospitalized Patient With...

CME/CE ·

2025/12/11

Faculty: Nancy S. Reau, MD This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing

en

314 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事